Market Positioned Target high-growth cancer screening and diagnostics markets leveraging Anpac Bio's CDA technology to pursue hospital systems and national labs seeking multi-cancer screening capabilities and early detection solutions.

Global Collaboration Capitalize on the company’s cross-border operations and joint publications by offering partnerships with research institutions, clinical networks, and academic centers to accelerate validation, studies, and regulatory pathways.

Growing Revenue Position for pilots and contracts in mid-market healthcare providers and private labs with expanding cancer screening programs, highlighting potential for scalable tests and downstream service/support revenues.

Strategic Expansion Leverage past facility expansion and CAP accreditation experience by offering deployment and implementation services for new labs, including equipment integration, quality systems, and regulatory readiness.

Thought Leadership Use recognitions and awards to build credibility in RFPs and proposals, targeting healthcare networks and payer conversations where innovation and breakthrough diagnostics can differentiate offerings.